Matches in SemOpenAlex for { <https://semopenalex.org/work/W1522136327> ?p ?o ?g. }
- W1522136327 abstract "Hashimoto's thyroiditis is a common auto-immune disorder. The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory. Clinical manifestations of the disease are defined primarily by low levels of thyroid hormones; therefore it is treated by hormone replacement therapy, which usually consists of levothyroxine (LT4). Selenium might reduce antibody levels and result in a decreased dosage of LT4 and may provide other beneficial effects (e.g. on mood and health-related quality of life).To assess the effects of selenium supplementation on Hashimoto's thyroiditis.We searched the following databases up to 2 October 2012: CENTRAL in The Cochrane Library (2012, Issue 10), MEDLINE, EMBASE, and Web of Science; we also screened reference lists of included studies and searched several online trial registries for ongoing trials (5 November 2012).Randomised controlled clinical trials that assessed the effects of selenium supplementation for adults diagnosed with Hashimoto's thyroiditis.Study selection, data extraction, assessment of risk of bias, and analyses were carried out by two independent review authors. We assessed the quality of the evidence of included studies using GRADE. We were unable to conduct a meta-analysis because clinical heterogeneity between interventions that were investigated is substantial.Four studies at unclear to high risk of bias comprising 463 participants were included. The mean study duration was 7.5 months (range 3 to 18 months). One of our primary outcomes－'change from baseline in health related quality of life'－and two of our secondary outcomes－'change from baseline in LT4 replacement dosage at end of the study' and 'economic costs'－were not assessed in any of the studies. One study at high risk of bias showed statistically significant improvement in subjective well-being with sodium selenite 200 μg plus titrated LT4 compared with placebo plus titrated LT4 (relative risk (RR) 4.67, 95% confidence interval (CI) 1.61 to 13.50; P = 0.004; 36 participants; number needed to treat (NNT) = 2 (95% CI 2 to 3)).Selenomethionine 200 μg reduced the serum levels of anti-thyroid peroxidase antibodies compared with placebo in two studies (mean difference (MD) -917 U/mL, 95% CI -1056 to -778; P < 0.001; 85 participants) and (MD -345 IU/mL, 95% CI -359 to -331; P < 0.001; 169 participants). Pooling of the studies was not feasible due to marked clinical heterogeneity (I(2) = 99%). In a further comparison within the first study where selenomethionine was combined with LT4 the reduction in TPO antibodies was even more noticeable (MD -1508 U/mL, 95% CI -1671 to -1345; P < 0.001; 86 participants). In a third study, where LT4 was added to both intervention arms, a reduction in serum levels of anti-thyroid peroxidase antibodies favoured the selenomethionine arm as well (MD -235 IU/mL, 95% CI -374 to -95; P = 0.001; 88 participants). Although the changes from baseline were statistically significant in these three studies, their clinical relevance is unclear. Serum antibodies were not statistically significantly affected in the study comparing sodium selenite 200 μg plus titrated LT4 with placebo plus titrated LT4 (MD -25, 95% CI -181 to 131; P = 0.75; 36 participants).Adverse events were reported in two studies (1 of 85 and 1 of 88 participants, respectively). Selenium supplementation did not appear to have a statistically significant impact on the incidence of adverse events (RR 2.93, 95% CI 0.12 to 70.00; and RR 2.63, 95% CI 0.11 to 62.95).Results of these four studies show that evidence to support or refute the efficacy of selenium supplementation in people with Hashimoto's thyroiditis is incomplete. The current level of evidence for the efficacy of selenium supplementation in the management of people with Hashimoto's thyroiditis is based on four randomised controlled trials assessed at unclear to high risk of bias; this does not at present allow confident decision making about the use of selenium supplementation for Hashimoto's thyroiditis. This review highlights the need for randomised placebo-controlled trials to evaluate the effects of selenium in people with Hashimoto's thyroiditis and can ultimately provide reliable evidence to help inform clinical decision making." @default.
- W1522136327 created "2016-06-24" @default.
- W1522136327 creator A5028843574 @default.
- W1522136327 creator A5042579611 @default.
- W1522136327 creator A5045912789 @default.
- W1522136327 creator A5046465972 @default.
- W1522136327 creator A5073181079 @default.
- W1522136327 date "2013-06-06" @default.
- W1522136327 modified "2023-09-27" @default.
- W1522136327 title "Selenium supplementation for Hashimoto's thyroiditis" @default.
- W1522136327 cites W127830848 @default.
- W1522136327 cites W1608321537 @default.
- W1522136327 cites W1646630 @default.
- W1522136327 cites W174924810 @default.
- W1522136327 cites W1839836563 @default.
- W1522136327 cites W1968194391 @default.
- W1522136327 cites W1977144711 @default.
- W1522136327 cites W1983261536 @default.
- W1522136327 cites W1987505986 @default.
- W1522136327 cites W1988609240 @default.
- W1522136327 cites W1989910801 @default.
- W1522136327 cites W1993076014 @default.
- W1522136327 cites W1996260234 @default.
- W1522136327 cites W2006313209 @default.
- W1522136327 cites W2006947222 @default.
- W1522136327 cites W2007718961 @default.
- W1522136327 cites W2011932878 @default.
- W1522136327 cites W2013188417 @default.
- W1522136327 cites W2018857232 @default.
- W1522136327 cites W2021894743 @default.
- W1522136327 cites W2026844201 @default.
- W1522136327 cites W2027918659 @default.
- W1522136327 cites W2032822376 @default.
- W1522136327 cites W2043464850 @default.
- W1522136327 cites W2046391772 @default.
- W1522136327 cites W2052475191 @default.
- W1522136327 cites W2057453845 @default.
- W1522136327 cites W2068352902 @default.
- W1522136327 cites W2075285534 @default.
- W1522136327 cites W2082447236 @default.
- W1522136327 cites W2098923148 @default.
- W1522136327 cites W2099736697 @default.
- W1522136327 cites W2117693444 @default.
- W1522136327 cites W2118998195 @default.
- W1522136327 cites W2135834945 @default.
- W1522136327 cites W2140936682 @default.
- W1522136327 cites W2141938606 @default.
- W1522136327 cites W2142296427 @default.
- W1522136327 cites W2144161407 @default.
- W1522136327 cites W2157823046 @default.
- W1522136327 cites W2159254479 @default.
- W1522136327 cites W2159946326 @default.
- W1522136327 cites W2161982303 @default.
- W1522136327 cites W2162212157 @default.
- W1522136327 cites W2164926351 @default.
- W1522136327 cites W2168365695 @default.
- W1522136327 cites W2169132215 @default.
- W1522136327 cites W2588142362 @default.
- W1522136327 cites W2588681363 @default.
- W1522136327 cites W3022903699 @default.
- W1522136327 cites W4214559180 @default.
- W1522136327 cites W4250376568 @default.
- W1522136327 doi "https://doi.org/10.1002/14651858.cd010223.pub2" @default.
- W1522136327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23744563" @default.
- W1522136327 hasPublicationYear "2013" @default.
- W1522136327 type Work @default.
- W1522136327 sameAs 1522136327 @default.
- W1522136327 citedByCount "38" @default.
- W1522136327 countsByYear W15221363272013 @default.
- W1522136327 countsByYear W15221363272014 @default.
- W1522136327 countsByYear W15221363272015 @default.
- W1522136327 countsByYear W15221363272016 @default.
- W1522136327 countsByYear W15221363272017 @default.
- W1522136327 countsByYear W15221363272018 @default.
- W1522136327 countsByYear W15221363272019 @default.
- W1522136327 countsByYear W15221363272020 @default.
- W1522136327 countsByYear W15221363272021 @default.
- W1522136327 countsByYear W15221363272022 @default.
- W1522136327 countsByYear W15221363272023 @default.
- W1522136327 crossrefType "journal-article" @default.
- W1522136327 hasAuthorship W1522136327A5028843574 @default.
- W1522136327 hasAuthorship W1522136327A5042579611 @default.
- W1522136327 hasAuthorship W1522136327A5045912789 @default.
- W1522136327 hasAuthorship W1522136327A5046465972 @default.
- W1522136327 hasAuthorship W1522136327A5073181079 @default.
- W1522136327 hasBestOaLocation W15221363271 @default.
- W1522136327 hasConcept C118552586 @default.
- W1522136327 hasConcept C126322002 @default.
- W1522136327 hasConcept C142724271 @default.
- W1522136327 hasConcept C168563851 @default.
- W1522136327 hasConcept C187212893 @default.
- W1522136327 hasConcept C204787440 @default.
- W1522136327 hasConcept C27081682 @default.
- W1522136327 hasConcept C2775883008 @default.
- W1522136327 hasConcept C2776478404 @default.
- W1522136327 hasConcept C2778696486 @default.
- W1522136327 hasConcept C2779134260 @default.
- W1522136327 hasConcept C2780733359 @default.
- W1522136327 hasConcept C526584372 @default.
- W1522136327 hasConcept C558461103 @default.